GCM
SUPN icon

Graham Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Graham Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,480
Closed -$330K – 1629
2025
Q2 		$330K Buy
10,480
+2,265
+28% +$72.6K 0.01% 964
2025
Q1 		$269K Buy
8,215
+1,307
+19% +$46.3K ﹤0.01% 1035
2024
Q4 		$250K Buy
+6,908
New +$243K ﹤0.01% 1003
2023
Q2 		– Sell
-9,965
Closed -$361K – 1287
2023
Q1 		$361K Buy
+9,965
New +$383K 0.01% 833

Other funds holding SUPN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Graham Capital Management's SUPN Position: Q3 2025 in Review

Graham Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2025, closing a stake of 10,480 shares — an estimated $330K sold.

Graham Capital Management first reported a position in SUPN in Q1 2023 and held it in 4 quarters. The position peaked at $361K in Q1 2023. 310 funds tracked by Wall St. Rank hold SUPN as of Q3 2025.

  • Graham Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
  • Graham Capital Management sold 10,480 Supernus Pharmaceuticals shares in Q3 2025, an estimated $330K.
  • Graham Capital Management first reported a position in Supernus Pharmaceuticals in Q1 2023 and held it in 4 quarters.
  • Graham Capital Management's Supernus Pharmaceuticals position peaked at $361K in Q1 2023.
  • 310 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2025.

Based on Graham Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.